Article citationsMore >>

Duarte, L. F., Farías, M. A., Álvarez, D. M., Bueno, S. M., Riedel, C. A., & González, P. A. (2019). Herpes simplex virus type 1 infection of the central nervous system: insights into proposed interrelationships with neurodegenerative disorders. Frontiers in Cellular Neuroscience, 13, 46.

has been cited by the following article:

Article

Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection

1Department of Biotechnology, HST Company, Cairo, Egypt

2Department of Biotechnology, HST Company


American Journal of Medical Sciences and Medicine. 2023, Vol. 11 No. 4, 98-101
DOI: 10.12691/ajmsm-11-4-1
Copyright © 2023 Science and Education Publishing

Cite this paper:
Hesham Mohamed Abdal-Salam Yehia, Said Mahmoud Said. Efficacy of OCTA-H and Octa-Gel Against Herpes Simplex Virus Type 1 Infection. American Journal of Medical Sciences and Medicine. 2023; 11(4):98-101. doi: 10.12691/ajmsm-11-4-1.

Correspondence to: Hesham  Mohamed Abdal-Salam Yehia, Department of Biotechnology, HST Company, Cairo, Egypt. Email: heshamyehia@gmail.com

Abstract

Herpes simplex virus type 1 (HSV-1) is a member of the Herpesviridae family and is a common human pathogen. Herpes simplex virus type 1 (HSV-1) infection is a highly prevalent viral infection that affects a large portion of the population worldwide. The development of effective antiviral agents to combat HSV-1 is of great importance. In this study, we aimed to evaluate the efficacy of two potential antiviral candidates, OCTA-H and Octa-Gel, against HSV-1 infection. The assay was conducted using a BSC-III cabinet level 3 III under Germfree conditions to ensure accurate assessment of antiviral activity. The results demonstrated that both OCTA-H and Octa-Gel exhibited significant antiviral activity against HSV-1, with OCTA-H demonstrating a higher level of efficacy compared to Octa-Gel. These findings highlight the potential of OCTA-H as a promising candidate for further development as an antiviral agent against HSV-1.

Keywords